Detalhe da pesquisa
1.
Simulation training for surgical residents in pediatric trauma scenarios.
Conn Med
; 76(3): 159-62, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22666976
2.
The prevalence of low muscle mass associated with obesity in the USA.
Skelet Muscle
; 12(1): 26, 2022 12 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-36539856
3.
Multifocal motor neuropathy: 30 years from onset to diagnosis.
Muscle Nerve
; 53(3): 490-1, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26562827
4.
Efficacy and Safety of Alirocumab in Patients With Autosomal Dominant Hypercholesterolemia Associated With Proprotein Convertase Subtilisin/Kexin Type 9 Gain-of-Function or Apolipoprotein B Loss-of-Function Mutations.
Am J Cardiol
; 125(6): 880-886, 2020 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31932084
5.
Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia: The ODYSSEY HoFH Trial.
J Am Coll Cardiol
; 76(2): 131-142, 2020 07 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-32646561
6.
Efficacy and safety of alirocumab in statin-intolerant patients over 3 years: open-label treatment period of the ODYSSEY ALTERNATIVE trial.
J Clin Lipidol
; 14(1): 88-97.e2, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32192644
7.
Effects of the ACE2 inhibitor GL1001 on acute dextran sodium sulfate-induced colitis in mice.
Inflamm Res
; 58(11): 819-27, 2009 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-19517214
8.
Comparison of use of the the Airtraq with direct laryngoscopy by paramedics in the simulated airway.
Prehosp Emerg Care
; 13(1): 75-80, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-19145529
9.
Pharmacokinetic and pharmacodynamic assessment of alirocumab in patients with familial hypercholesterolemia associated with proprotein convertase subtilisin/kexin type 9 gain-of-function or apolipoprotein B loss-of-function mutations.
J Clin Lipidol
; 13(6): 970-978, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31767518
10.
Short-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: a 28-day, open-label study.
Clin Ther
; 30(9): 1658-66, 2008 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-18840371
11.
The fifth vital sign--what does it mean?
Pain Pract
; 8(6): 417-22, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-18662363
12.
Tolerability, pharmacokinetics, and neuroendocrine effects of PRX-00023, a novel 5-HT1A agonist, in healthy subjects.
J Clin Pharmacol
; 47(7): 817-24, 2007 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-17495280
13.
Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial.
Atherosclerosis
; 244: 138-46, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26638010
14.
Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial.
J Clin Endocrinol Metab
; 100(8): 3140-8, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26030325
15.
Pharmacokinetics and pharmacodynamics of glyburide/metformin tablets (Glucovance) versus equivalent doses of glyburide and metformin in patients with type 2 diabetes.
Clin Pharmacokinet
; 41(15): 1301-9, 2002.
Artigo
em Inglês
| MEDLINE | ID: mdl-12452739
16.
A review and assessment of potential sources of ethnic differences in drug responsiveness.
J Clin Pharmacol
; 43(9): 943-67, 2003 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-12971027
17.
Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS Studies.
Clin Cardiol
; 37(10): 597-604, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25269777
18.
Economic impact model for the development of a statewide trauma system in Georgia.
J Med Assoc Ga
; 96(3): 10-3, 2007.
Artigo
em Inglês
| MEDLINE | ID: mdl-18203550
19.
Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial.
J Clin Psychopharmacol
; 28(2): 235-9, 2008 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-18344738